DK3436593T3 - Fremgangsmåder til varmeinaktivering af adenovirus - Google Patents

Fremgangsmåder til varmeinaktivering af adenovirus Download PDF

Info

Publication number
DK3436593T3
DK3436593T3 DK17776462.8T DK17776462T DK3436593T3 DK 3436593 T3 DK3436593 T3 DK 3436593T3 DK 17776462 T DK17776462 T DK 17776462T DK 3436593 T3 DK3436593 T3 DK 3436593T3
Authority
DK
Denmark
Prior art keywords
adenovirus
methods
heat inactivation
inactivation
heat
Prior art date
Application number
DK17776462.8T
Other languages
English (en)
Inventor
James D Maratt
Christopher J Morrison
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Application granted granted Critical
Publication of DK3436593T3 publication Critical patent/DK3436593T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK17776462.8T 2016-03-28 2017-03-28 Fremgangsmåder til varmeinaktivering af adenovirus DK3436593T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314116P 2016-03-28 2016-03-28
PCT/US2017/024545 WO2017172772A1 (en) 2016-03-28 2017-03-28 Methods of heat inactivation of adenovirus

Publications (1)

Publication Number Publication Date
DK3436593T3 true DK3436593T3 (da) 2023-02-20

Family

ID=59966403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17776462.8T DK3436593T3 (da) 2016-03-28 2017-03-28 Fremgangsmåder til varmeinaktivering af adenovirus

Country Status (18)

Country Link
US (3) US11013774B2 (da)
EP (2) EP3436593B1 (da)
JP (3) JP7356224B2 (da)
KR (1) KR102389674B1 (da)
CN (1) CN109196106A (da)
AU (1) AU2017241777B2 (da)
BR (1) BR112018069703A2 (da)
CA (1) CA3018380A1 (da)
DK (1) DK3436593T3 (da)
ES (1) ES2938833T3 (da)
FI (1) FI3436593T3 (da)
HU (1) HUE061100T2 (da)
IL (1) IL261914B2 (da)
LT (1) LT3436593T (da)
PL (1) PL3436593T3 (da)
PT (1) PT3436593T (da)
SG (1) SG11201808183PA (da)
WO (1) WO2017172772A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
RU2749882C2 (ru) 2014-11-14 2021-06-18 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2019266454A1 (en) * 2018-05-11 2020-10-15 Qiagen Gmbh Lysis method for plant samples
CN113454226A (zh) 2018-12-18 2021-09-28 阿尔特拉吉尼克斯制药公司 用于治疗糖原贮积病的方法和组合物
BR112021020391A2 (pt) 2019-04-12 2022-02-08 Ultragenyx Pharmaceutical Inc Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas
TW202342740A (zh) 2022-03-07 2023-11-01 美商奧崔基尼克斯製藥公司 改良的批量aav生產系統和方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えdnaウイルスベクター
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5688676A (en) * 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
ES2099678B1 (es) * 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
AU741605B2 (en) 1996-12-18 2001-12-06 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
IT1297074B1 (it) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
CA2340682A1 (en) * 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
JP2002528087A (ja) 1998-10-27 2002-09-03 クルセル ホランド ベー ヴェー 改良aavベクター産生
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
HUP0200821A3 (en) * 1999-04-09 2004-11-29 Centelion Composition for the preservation of infectious recombinant adenoviruses
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
DE10061533B4 (de) 2000-12-11 2006-05-04 Amphenol-Tuchel Electronics Gmbh Selbsttragende Kontaktfeder, insbesondere für einen Smartcard-Connector
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
CA2569244C (en) * 2004-06-01 2017-02-14 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
US7195394B2 (en) 2004-07-19 2007-03-27 Vijay Singh Method for resonant wave mixing in closed containers
US8980247B2 (en) 2004-10-21 2015-03-17 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
EP2010557B1 (en) * 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
GB0706638D0 (en) 2007-04-04 2007-05-16 Mbda Uk Ltd A high-dielectric material
US8580755B2 (en) 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
CA2742151A1 (en) 2008-11-07 2010-05-14 Intelligentnano Inc. Transfection with magnetic nanoparticles and ultrasound
SG176283A1 (en) * 2009-06-16 2012-01-30 Genzyme Corp Improved methods for purification of recombinant aav vectors
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
CA2897444A1 (en) 2013-01-08 2014-07-17 Genzyme Corporation Use of inos inhibitors to increase viral yield in culture

Also Published As

Publication number Publication date
ES2938833T3 (es) 2023-04-17
HUE061100T2 (hu) 2023-05-28
US20220072073A1 (en) 2022-03-10
EP3436593A1 (en) 2019-02-06
WO2017172772A1 (en) 2017-10-05
IL261914A (en) 2018-10-31
FI3436593T3 (fi) 2023-03-16
IL261914B2 (en) 2023-07-01
US11944658B2 (en) 2024-04-02
US11013774B2 (en) 2021-05-25
JP2022166304A (ja) 2022-11-01
SG11201808183PA (en) 2018-10-30
CA3018380A1 (en) 2017-10-05
AU2017241777A1 (en) 2018-10-11
BR112018069703A2 (pt) 2019-02-05
JP7356224B2 (ja) 2023-10-04
KR20180130531A (ko) 2018-12-07
JP2019509747A (ja) 2019-04-11
CN109196106A (zh) 2019-01-11
EP3436593A4 (en) 2019-10-16
US20190083554A1 (en) 2019-03-21
EP4159867A1 (en) 2023-04-05
KR102389674B1 (ko) 2022-04-21
PT3436593T (pt) 2023-01-31
LT3436593T (lt) 2023-03-10
US20240252562A1 (en) 2024-08-01
JP2021072838A (ja) 2021-05-13
EP3436593B1 (en) 2022-11-23
PL3436593T3 (pl) 2023-03-27
AU2017241777B2 (en) 2022-02-03
IL261914B1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
DK3436593T3 (da) Fremgangsmåder til varmeinaktivering af adenovirus
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3183505T3 (da) Underlag til positionering af varmeelementer og gulvanlæg
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese
DK3261726T3 (da) Sammensætning til behandling af acne
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3363148T3 (da) Afdækning af krypteringsanvendelse
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner